» Articles » PMID: 16755346

Testosterone Hormone Replacement Therapy: State-of-the-art and Emerging Technologies

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2006 Jun 7
PMID 16755346
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

In the human male, testosterone is the major circulating androgen. The clinical effects of androgen are numerous, and testosterone deficiency is associated with a number of clinical abnormalities. At present, a variety of preparations containing testosterone is available for the treatment of androgen deficiency. Ideally, those treatments have to produce and maintain physiologic serum concentrations of the hormone. This article reviews the current existing testosterone dosage forms on the market with their advantages and drawbacks and examines new and emerging technology developments concerning this therapy. In particular, the latest innovations in transdermal delivery are explored.

Citing Articles

Testosterone Use in Adolescent Males: Current Practice and Unmet Needs.

Vogiatzi M, Tursi J, Jaffe J, Hobson S, Rogol A J Endocr Soc. 2020; 5(1):bvaa161.

PMID: 33294762 PMC: 7705876. DOI: 10.1210/jendso/bvaa161.


Klinefelter syndrome presenting as behavioral problems in a young adult.

Molnar A, Terasaki G, Amory J Nat Rev Endocrinol. 2010; 6(12):707-12.

PMID: 20957000 PMC: 4271651. DOI: 10.1038/nrendo.2010.186.

References
1.
Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R . AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003; 88(6):2673-81. DOI: 10.1210/jc.2002-021058. View

2.
Snyder P, Peachey H, Hannoush P, Berlin J, Loh L, Holmes J . Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999; 84(6):1966-72. DOI: 10.1210/jcem.84.6.5741. View

3.
Behre H, Abshagen K, Oettel M, Hubler D, Nieschlag E . Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol. 1999; 140(5):414-9. DOI: 10.1530/eje.0.1400414. View

4.
Behre H, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E . Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab. 1995; 80(8):2394-403. DOI: 10.1210/jcem.80.8.7543113. View

5.
Conway A, Boylan L, Howe C, Ross G, Handelsman D . Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl. 1988; 11(4):247-64. DOI: 10.1111/j.1365-2605.1988.tb00999.x. View